Orexa is a clinical-stage pharmaceutical company that develops and commercializes therapeutics to increase food intake. Its lead compound is a proprietary oral formulation for human use, based on a well known anesthetic. The company is in preparation for phase 2a studies in Post-Operative Ileus and Cachexia, two indications whereby increased food intake could lead to an improved patient health, a shorter hospital stay and significant cost savings. Orexa was founded in 2016 and is headquartered in Herpen (Oss Region, Noord Brabant), The Netherlands.
CEO / CFO
Actuarial Sciences (University of Amsterdam)
Early investor in AM-Pharma.
CFO of Alloksys Life Sciences
Venture Partner of NextStage Early Stage Fund
CSO / Founder of Orexa
PhD in Psychology
Professor in Behavioural Pharmacology (Radboud UMC, Nijmegen)
Organon, Schering Plough, MSD
Within Organon Ard was responsible for the development of brain active (CNS) drugs.
Geeske In ‘t Velt 海思柯
Business Development China
MA Chinese Studies & International Management (Leiden University)
Extensive experience in China related business development, with a focus on Life Sciences.
“We have found a very strong signal in our pre-clinical research and successfully completed a Phase 1 study.
Now we are in the most exciting stage: will our mechanism of action also work in patients in Phase 2 ?”
Prof. Dr. Ard Peeters